PMID- 25436170
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20141201
LR  - 20200930
IS  - 2090-8059 (Print)
IS  - 2042-0064 (Electronic)
IS  - 2042-0064 (Linking)
VI  - 2014
DP  - 2014
TI  - The therapeutic effectiveness of the coadministration of weekly risedronate and 
      proton pump inhibitor in osteoporosis treatment.
PG  - 607145
LID - 10.1155/2014/607145 [doi]
LID - 607145
AB  - This trial was conducted to investigate the long-term effects of proton pump 
      inhibitor (PPI) coadministration on the efficacy of weekly risedronate treatment 
      for osteoporosis. Ninety-six women over 50 years old with low bone mineral 
      density (BMD) participated in this trial. Subjects were randomly divided into 2 
      groups: a 17.5 mg dose of sodium risedronate was administered weekly, with or 
      without a daily 10 mg dose of sodium rabeprazole (n = 49 and 47 in the BP + PPI 
      and BP groups, resp.). The following biomarkers were measured at the baseline and 
      every 3 months: bone-specific alkaline phosphatase, N-terminal telopeptide of 
      type I collagen corrected for creatinine, parathyroid hormone, BMD of the lumbar 
      spine, and physical parameters evaluated according to the SF-36v2 Health Survey. 
      Statistical comparisons of these parameters were performed after 6, 12, 18, and 
      24 months. The Delta values of improvement in physical functioning after 12 months 
      and bodily pain after 6 and 12 months in the BP + PPI group were significantly 
      larger than those in the BP group. These results suggest that PPI does not 
      adversely affect bone metabolism. Alternatively, approved bone formation by 
      concomitant PPI treatment may have had favorable effects on the improvement of 
      bodily pain and physical functions.
FAU - Tanaka, Mizue
AU  - Tanaka M
AD  - Department of Orthopaedic Surgery, Kawakita General Hospital, 1-7-3 Asagaya-kita, 
      Suginami-ku, Tokyo 166-8588, Japan.
FAU - Itoh, Soichiro
AU  - Itoh S
AUID- ORCID: 0000-0002-8904-4186
AD  - Department of Orthopaedic Surgery, Kawakita General Hospital, 1-7-3 Asagaya-kita, 
      Suginami-ku, Tokyo 166-8588, Japan ; Department of Orthopaedic Surgery, Sakurakai 
      Hospital, 2-13-1 Senju Sakuragi, Adachi-ku, Tokyo 120-0045, Japan ; Department of 
      Inorganic Materials, Institute of Biomaterials and Bioengineering, Tokyo Medical 
      and Dental University, 2-3-10 Kanda-Surugadai, Chiyoda, Tokyo 101-0062, Japan.
FAU - Yoshioka, Taro
AU  - Yoshioka T
AD  - Department of Orthopaedic Surgery, Kawakita General Hospital, 1-7-3 Asagaya-kita, 
      Suginami-ku, Tokyo 166-8588, Japan.
FAU - Yamashita, Kimihiro
AU  - Yamashita K
AD  - Department of Inorganic Materials, Institute of Biomaterials and Bioengineering, 
      Tokyo Medical and Dental University, 2-3-10 Kanda-Surugadai, Chiyoda, Tokyo 
      101-0062, Japan.
LA  - eng
PT  - Journal Article
DEP - 20141109
PL  - United States
TA  - J Osteoporos
JT  - Journal of osteoporosis
JID - 101538878
PMC - PMC4241743
EDAT- 2014/12/02 06:00
MHDA- 2014/12/02 06:01
PMCR- 2014/11/09
CRDT- 2014/12/02 06:00
PHST- 2014/07/28 00:00 [received]
PHST- 2014/10/11 00:00 [revised]
PHST- 2014/10/12 00:00 [accepted]
PHST- 2014/12/02 06:00 [entrez]
PHST- 2014/12/02 06:00 [pubmed]
PHST- 2014/12/02 06:01 [medline]
PHST- 2014/11/09 00:00 [pmc-release]
AID - 10.1155/2014/607145 [doi]
PST - ppublish
SO  - J Osteoporos. 2014;2014:607145. doi: 10.1155/2014/607145. Epub 2014 Nov 9.